Literature DB >> 16434330

Outcomes after supratherapeutic escitalopram ingestions.

Frank LoVecchio1, David Watts, Joseph Winchell, Jason Knight, Tim McDowell.   

Abstract

Escitalopram (ESC) is a new selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression. There are limited data regarding accidental and intentional ESC exposure. We conducted a retrospective chart review of isolated ESC ingestions reported to our regional poison center during 2003-2004. Twenty-eight patients met inclusion criteria. The average patient age was 28.1 years (range 2-75 years) and the average amount of ESC ingested was 62.5 mg (range 5-300 mg from 19 cases). The most common formulation ingested was the 20-mg tablet. There were eight accidental ingestions and 20 intentional overdoses. Six of the eight accidental ingestions were observed at home with follow-up in 24 h, and no adverse outcomes were reported. The other two accidental overdoses were observed in the Emergency Department (ED) and discharged home with no adverse events reported. Nineteen of the intentional overdoses were observed in the ED for approximately 4-6 h and discharged home or to an inpatient psychiatry ward. One of the intentional overdose patients was admitted for persistent lethargy, but had a good outcome. ESC toxicity can theoretically be life threatening, but no patients in our series had adverse sequealae after accidental or intentional overdose.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434330     DOI: 10.1016/j.jemermed.2005.04.013

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  3 in total

Review 1.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines.

Authors:  Adrian Baranchuk; Christopher S Simpson; Michelle Methot; Kara Gibson; David Strum
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

3.  Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.

Authors:  Eiji Kirino
Journal:  Patient Prefer Adherence       Date:  2012-12-04       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.